Search
Close this search box.

Cerebrolysin in Hong Kong

Improves Motor and Cognitive Functions in Stroke and TBI

Improves Cognitive performance in demantiac

Helps prevent Cognitive decline after stroke and TBI

What is cerebrolysin

Cerebrolysin is a multifaceted peptide-based drug with diverse pharmacological properties. It is used to help treating a variety of acute and chronic central nervous system (CNS) disorders. Cerebrolysin has been shown to modulate two key signaling pathways:

  1. Neurotrophic Factor (NTF) Pathway: This pathway helps maintain, protect, and restore neuronal networks, ensuring proper brain function.
  2. Sonic Hedgehog (Shh) Signaling Pathway: This pathway regulates the development of organs, including the organization and structure of the brain.

By targeting these critical signaling cascades, Cerebrolysin aims to provide neuroprotective and restorative effects in the treatment of various CNS conditions.

Therapeutic Areas

Stroke

Stroke

Disturbed or interrupted
blood flow in the brain

Traumatic Brain Injury

Brain Injury

Damage to neuronal structures and brain substances

Neurocognitive Disorders

Neurodegenerative processes kill neurons and disrupt neuronal networks

Pathophysiological Challenges:

  • Disruption of the brain’s regulatory processes including those controlled by neurotrophic factors (NTFs)
  • Local deprivation of NTFs in the affected brain tissue

Acute Phase
Rehabilitation Phase

Traumatic Brain Injury

Treatment Prevention

After primary damages the affected part of the brain develops a secondary pathological cascade

  • Uncontrolled apoptosis
  • Excessive neuroinflammation
  • Formation of free radicals 
  • Excitotoxcity
  • Neuronal Dysregulation
  • Neurodegeneration

A multi-modal drug for acute and post-acute neurological disorder

Boosts Faster Recovery

  • Combination therapy Cerebrolysin with rtPA results in faster recovery than rtPA alone. 
  • Cerebrolysin shifts the day 90 responder rate forward to day 10 
  • Early add-on of cerebrolysin to reperfusion therapy reduces risk of hemorrhagic transformation by -40%

IMproves Motor Functions

  • Significant improvement of upper limb motor functions by +88% with structured rehabilitation
  • Recovery was faster and showed long-term effects in Cerebrolysin group

Effective treatment after TBI

Results from CAPTAIN II trial

  • Treatment with Cerebrolysin shows improvement of global outcome in moderate-severe TBI patients at 90 days as compared to placebo
  • 6 out of 7 single outcome scales showing the superiority of Cerebrolysin already on day 10

In the meta-analysis of the CAPTAIN Trail Series by Vester et.al

  • 70.5% of Cerebrolysin patients recover from depression after TBI
  • +31% more Cerebrolysin patients show normalization in HADS depression score vs placebo

Cerebrolysin Inclusion in Evidence-Based
Review of moderate to severe Acquired Brain Injury

Conclusion: 
  • There is level 1b evidence that Cerebrolysin is an effective therapy that may improve attentional function for individuals living with moderate to severe TBI. 

Improves cognitive performance in Alzheimer's Disease (AD)

  • Cerebrolysin 10ml in combination with donepezil was more effective than monotherapy in mild-to-moderate AD patient
  • The combination of cerebrolysin with Donepezil is a sage treatment option
  • In a study to access the。ffect Cerebrolysin inpatient with more advanced forms of AD
  • Patients treated with Cerebrolysin were improved significantly, resulting in a treatment difference of 4.1 points (p<0.001) compared to long term beneficial effects on Cognition

Improves cognitive functions in vascular dementia (VaD)​

  • In a 24-week, randomized, double-blind, placebo-controlled study in VaD patient
  • ADAS-cog+ in patients with Cerebrolysin is significantly improved at week 24 (p<0.0001)
  • The CIBIC+ assessement shows  a signifant improvement in。erebrolysin group(75.3% vs 37.4% in placebo group)

Cerebrolysin is safe and well tolerated

ACcording to EMA Classification, cerebrolysin is in the safe category.

A comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo. 

Clinical Benefits for Patients

Treatment of neurological disorders with Cerebrolysin helps to increase the quality of life for patients.

Stroke

  • Early Recovery
  • Improvement of motor functions
  • Regained independence
  • Increased quality of life
  • Improvement of cognitive functions
  • higher survival ratre 

Traumatic Brain Injury

  • Effective treatment after TBI
  • Save lives
  • Early recovery
  • Better Quality of life
  • Improvement and concentration

Neurocognitive Disorders

  • Improvement of cognitive performance 
  • Higher quality of life
  • Prolong active an independent life
  • Prevention of behavioural disorders